Background
Methods
Study participants
Herpes simplex virus type 2 (HSV-2) detection, high-risk HPV type detection and papanicolau test
Clinical specimens, extraction of genomic DNA and genotyping
Statistical analysis
Results
Characteristics | Cases | Controls | P-value# | ||
---|---|---|---|---|---|
Black | Mixed-ancestry | Black | Mixed-ancestry | ||
Number of subjects | 104 | 338 | 52 | 226 | |
Age (years), mean ± SD | 43.7 ± 9.3 | 45.9 ± 8.1 | 40.8 ± 8.9 | 45.5 ± 8.1 | 0.271 |
Smoking | |||||
Positive | 82 | 53 | 44 | 67 | 0.012 |
Negative | 22 | 285 | 8 | 159 | |
HSV-2 infection | |||||
Infected | 93 | 198 | 47 | 117 | 0.161 |
Non-infected | 10 | 128 | 3 | 96 | |
HIV infection | |||||
Infected | 13 | 9 | 4 | 7 | 0.589 |
Non-infected | 89 | 322 | 46 | 206 | |
HPV infection | |||||
Infected | 12 | 35 | 0.539 | ||
Non-infected | 26 | 97 | |||
Abnormal cytology | |||||
Positive | 12 | 23 | 0.013 | ||
Negative | 39 | 195 | |||
High-risk HPV infection | |||||
Positive | 7 | 32 | 0.862 | ||
Negative | 44 | 186 |
Black Africans and Mixed Ancestry combined | |||
Haplotype or Genotype combinations | Cases, n = 442 (frequency) | Controls, n = 278 (frequency) | P-value (global) |
CASP8 + FasR-1377
| 87 (49) | 92 (51) | 0.531 |
CASP8 + FasR-670
| 98 (50) | 99 (50) | 0.63 |
CASP8 + FasL-844
| 97 (50) | 98 (50) | 0.738 |
CASP8 + FasR-1377 + FasR-670
| 86 (48) | 92 (52) | 0.813 |
CASP8 + FasR-1377 + FasL-844
| 85 (48) | 91 (52) | 0.771 |
CASP8 + FasR-670 + FasL-844
| 95 (50) | 97 (50) | 0.937 |
CASP8 + FasR-1377 + FasR-670 + FasL-844
| 84 (48) | 90 (52) | 0.978 |
Among Black Africans | |||
Combined Polymorphisms | Cases, n = 104 (frequency) | Controls, n = 52 (frequency) | P-value (global) |
CASP8 + FasR-1377
| 96 (66) | 49 (34) | 0.138 (global P) |
−652 6 N ins and G | (41) | (28) | 0.047 (CPS = 1.99) |
CASP8 + FasR-670
| 103 (67) | 51 (33) | 0.028 (global P) |
−652 6 N del and A | (6) | (19) | 0.019 (CPS = −2.34) |
CASP8 + FasL-844
| 103 (67) | 51 (33) | 0.1 (global P) |
CASP8 + FasR-1377 + FasR-670
| 96 (67) | 48 (33) | 0.131 (global P) |
−652 6 N del, G and A | (6) | (19) | 0.019 (CPS = −2.35) |
CASP8 + FasR-1377 + FasL-844
| 95 (66) | 48 (34) | 0.181 (global P) |
CASP8 + FasR-670 + FasL-844
| 102 (67) | 50 (33) | 0.047 (global P) |
−652 6 N del, A and C | (1) | (7) | 0.018 (CPS = −2.36) |
CASP8 + FasR-1377 + FasR-670 + FasL-844
| 95 (67) | 47 (33) | 0.115 (global P) |
−652 6 N del, G, A and C | (9) | (7) | 0.027 (CPS = −2.21) |
Among Mixed-Ancestry group | |||
Haplotypes | Cases, n = 338 (frequency) | Controls, n = 226 (frequency) | P-value (global) |
CASP8 + FasR-1377
| 289 (58) | 208 (42) | 0.747 |
CASP8 + FasR-670
| 330 (59) | 225 (41) | 0.966 |
CASP8 + FasL-844
| 326 (59) | 222 (41) | 0.909 |
CASP8 + FasR-1377 + FasR-670
| 282 (58) | 207 (42) | 0.971 |
CASP8 + FasR-1377 + FasL-844
| 280 (58) | 204 (42) | 0.924 |
CASP8 + FasR-670 + FasL-844
| 320 (59) | 221 (41) | 0.991 |
CASP8 + FasR-1377 + FasR-670 + FasL-844
| 275 (58) | 203 (42) | 0.996 |
Combined Polymorphisms | HSV-2 infected Frequency (n = 164) | HSV-2 non-infected Frequency (n = 99) | Combined Polymorphism Score | P-value |
---|---|---|---|---|
Casp8 + FasR-1377 (global P = 0.134) | ||||
−652 6 N ins and A | 7 | 12 | −2.28 | 0.023 |
Casp8 + FasR-1377 + FasR-670 (global P = 0.164) | ||||
−652 6 N ins, A and G | 7 | 12 | −2.17 | 0.03 |
Casp8 + FasR-1377 + FasR-670 + FasL-844 (global P = 0.324) | ||||
−652 6 N ins, A, G and T | 16 | 22 | −2.13 | 0.033 |